Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i-GO: ThermoDox + MR-HIFU in Metastatic Breast Cancer
NCT03749850Phase 1Unknown
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doxorubicin in breast cancer. Primary endpoints: Incidence of adverse events assessed by CTCAE v 5.0, Incidence of dose limiting toxicities and 9 more. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03749850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03749850.